1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Leaks And Prejudice Must End In US Multi-State Pricing Case

 
• By Dave Wallace

A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.

Shhh
Leaks and allegations must be silenced, the firms say • Source: Shutterstock

In a filing that reads like a Who’s Who of top generics firms, more than a dozen companies have asked a Pennsylvania district court to intervene with an order to stop parties to a multi-state lawsuit over generics pricing from leaking information and releasing prejudicial information to the press.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

 
• By Dave Wallace

Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”

More from Policy & Regulation

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab

 
• By Dave Wallace

Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.